The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER; Vantana
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Clovis Oncology; GIC Advice; GIC Advice; HalioDX; MSD Oncology; Roche/Genentech; SERVIER; Tesaro
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; MSD Oncology; Roche; Roche/Genentech; Vantana
 
Kai-Keen Shiu
Honoraria - Bristol-Myers Squibb; Guardant Health; Innovent Biologics
Consulting or Advisory Role - Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck KGaA (Inst); MSD Brazil (Inst)
Travel, Accommodations, Expenses - MSD Brazil
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Sanofi (Inst)
 
Benny Vittrup Jensen
No Relationships to Disclose
 
Lars Henrik Jensen
Research Funding - 2cureX (Inst); BMS (Inst); Incyte (Inst); MSD (Inst)
 
Cornelis J. A. Punt
Consulting or Advisory Role - Bayer (Inst); Nordic Pharma (Inst)
Travel, Accommodations, Expenses - Nordic Pharma
 
Denis Michel Smith
Honoraria - Advanced Accelerator Applications; Ipsen; Sanofi
 
Rocio Garcia-Carbonero
Honoraria - ADACAP; Advanz Pharma; AstraZeneca (I); Boehringer Ingelheim (I); BRISTOL-MYERS SQUIBB; Bristol-Myers Squibb (I); Gilead Sciences (I); HMP; Ipsen; Lilly (I); MERCK; Merck (I); Midatech Pharma; NOVARTIS; PFIZER; PharmaMar; PharmaMar (I); Pierre Fabre; ROCHE; Roche (I); Sanofi; SERVIER; SERVIER (I); Sysmex (I)
Consulting or Advisory Role - AAA; HMP; Ipsen; Novartis; Pfizer
Speakers' Bureau - Ipsen; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Merck; Roche
 
Manuel Benavides
Consulting or Advisory Role - Amgen; Merck; Roche; Sanofi
 
Peter Gibbs
Honoraria - Amgen; Merck; MSD Oncology; Roche; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Merck Serono (Inst); Roche (Inst); Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - Servier
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER; Shire
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER
 
Fernando Rivera
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Brazil; Roche; Sanofi; SERVIER LABORATORIES LTD
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Brazil; Roche; Sanofi; SERVIER LABORATORIES LTD
Research Funding - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Brazil; Roche; Sanofi; SERVIER LABORATORIES LTD
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Brazil; Roche; Sanofi; SERVIER LABORATORIES LTD
 
Elena Elez
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Pierre Fabre; Roche; Sanofi; SERVIER
Research Funding - Merck Serono; Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Sanofi
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seattle Genetics (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Biopharma (Inst); Gritstone Oncology (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seattle Genetics (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx, Inc (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TempestTx (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Dung T. Le
Honoraria - Merck
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Curegenix; Medivir; Merck
Patents, Royalties, Other Intellectual Property - Inventor of technology, "Microsatellite Instability as a Pharmacogenomic Marker of Therapeutic Response to Immune Checkpoint Inhibition".
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); GlaxoSmithKline plc (Inst); MSD.K.K. (Inst); Novartis Pharma K.K. (Inst); ONO PHARMACEUTICAL CO., LTD. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Ping Yang
Employment - Merck
Stock and Other Ownership Interests - Merck/Schering Plough
 
Mohammed Zulfiqar Husain Farooqui
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Patricia Marinello
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Jounce Therapeutics; Neophore; PapGene, Inc.; Personal Genome Diagnostics; Thrive Detect; Zydecom Corporation
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra; Merck; Neophore; Personal Genome Diagnostics; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck